Bright Minds Biosciences
Vancouver
About Bright Minds Biosciences
Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $338.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: cse:DRUG
- Website: brightmindsbio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Mental Health
Social Profiles
Canonical: https://fsome.com/organization/bright-minds-biosciences-43161 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.